| 0.69 0 (0%) | 04-24 11:20 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.95 | 1-year : | 1.13 |
| Resists | First : | 0.82 | Second : | 0.97 |
| Pivot price | 0.76  |
|||
| Supports | First : | 0.57 | Second : | 0.48 |
| MAs | MA(5) : | 0.66 |
MA(20) : | 0.76 |
| MA(100) : | 0.71 |
MA(250) : | 1.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.7 |
D(3) : | 22 |
| RSI | RSI(14): 43.8 | |||
| 52-week | High : | 2.44 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ THMO ] has closed above bottom band by 30.2%. Bollinger Bands are 9.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.72 - 0.72 | 0.72 - 0.73 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.68 - 0.69 | 0.69 - 0.7 |
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
Fri, 15 Mar 2024
THMO Stock Quote Price and Forecast - CNN
Thu, 29 Feb 2024
Analysts Expect ThermoGenesis Holdings, Inc. (NASDAQ:THMO) To Breakeven Soon - Simply Wall St
Tue, 27 Feb 2024
ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Is About To Turn The Corner - Yahoo Finance
Wed, 15 Mar 2023
ThermoGenesis Rolls Out Manufacturing Suites For Use In Early-Stage Cell, Gene Therapy, Shares Soar - Yahoo Finance
Wed, 15 Mar 2023
Why ThermoGenesis Stock Is Soaring Wednesday - The Motley Fool
Wed, 15 Mar 2023
THMO Stock Alert: Why ThermoGenesis Is Up 95% Today - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 8 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 55 (K) |
| Shares Short P.Month | 106 (K) |
| EPS | -7.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.47 |
| Profit Margin | -190.4 % |
| Operating Margin | -93.2 % |
| Return on Assets (ttm) | -26.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -10.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.18 |
| EBITDA (p.s.) | -0.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | -1.5 |
| Price to Sales | 0.58 |
| Price to Cash Flow | -1.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|